People · Operator
Named in public records as an officer, director or promoter · active 2008–2021 · Biotechnology, Biotech, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | — | Biotechnology | Series C | $143.0M | $3.0B | 2020 |
| CymaBay Therapeutics, Inc. | — | Biotechnology | Series B | $90.6M | $12.9M | 2008 |
| Flexion Therapeutics Inc | — | Biotechnology | Series B | $40.0M | $793.8M | 2009 |
| Mistral Therapeutics, Inc. | — | Biotechnology | Series B | $36.4M | $1.0B | 2018 |
| CRISPR Therapeutics AG | — | Biotech | Series B | $36.0M | $39.7M | 2020 |
| Northern Mosaic LP | — | Biotechnology | Series A | $7.3M | $263.6M | 2019 |
| Inception IBD, Inc. | — | Pharmaceuticals | Series A | $6.9M | $214.3M | 2015 |
| Inception 4, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2013 |
| Inception 5, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2014 |
| Inception 3, Inc. | — | Biotechnology | Seed | $1.1M | $47.1M | 2012 |
BRADLEY BOLZON at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside BRADLEY BOLZON on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Petpiboon Prasit | 5 | 7 |
| Jerel Davis | 3 | 13 |
| Ali Behbahani | 2 | 17 |
| Clare Ozawa | 2 | 8 |
| Andrew Schwab | 1 | 16 |
| Heath Lukatch | 1 | 10 |
| Simeon George | 1 | 8 |
| Thomas Woiwode | 1 | 7 |
| Anthony Evnin | 1 | 6 |
| Elaine Jones | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| Robert Zerbe | 1 | 5 |
| Bradley J. Bolzon | 1 | 5 |
| Carl Goldfischer | 1 | 5 |
| THOMAS A COLL | 1 | 4 |
| Jeremy Caldwell | 1 | 4 |
| Alexander Mayweg | 1 | 4 |
| SAMUEL COLELLA | 1 | 3 |
| Kim Blackwell | 1 | 3 |
| Darlene Deptula-Hicks | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.